Video

Methotrexate May Benefit Juvenile Scleroderma

Publish date: October 7, 2010

 

Children with localized scleroderma responded better to methotrexate than to prednisone in a small, placebo-controlled trial, Dr. Francesco Zulian reports.

View Video Now.

Recommended Reading

For Kids' Pain, Opioid Combo Equals Ibuprofen
MDedge Rheumatology
Cancer Risk in JIA Is Not a Treatment Effect
MDedge Rheumatology
Methotrexate-Related GI Upset Common in JIA
MDedge Rheumatology
Joint-Sparing Surgery Helps Ease Deformities
MDedge Rheumatology
Obesity at Age 18 Found to Increase PsA Risk
MDedge Rheumatology
Global Data: Cancer Very Rare in Children on Etanercept
MDedge Rheumatology
Tocilizumab Shows Efficacy for Systemic JIA : These data are proof of the principle that many patients seem to benefit from blocking IL-6.
MDedge Rheumatology
How to Deliver Bad News to Parents of Pediatric Patients
MDedge Rheumatology
Child's Fever, Limp May Be Septic Arthritis
MDedge Rheumatology
Lung Function Often Impaired in Juvenile Dermatomyositis
MDedge Rheumatology